Healthcare Services

One of the Major Drivers of the Menopausal Hot Flashes Market Is the Government-Led Menopausal Health Initiatives Is A Catalyst For Growth In The Menopausal Hot Flashes Market

April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Menopausal Hot Flashes Market Projected To Become By 2030 Based On Its 2026 Valuation?

The menopausal hot flashes market size has experienced robust growth in recent years. It is projected to expand from $15.92 billion in 2025 to $16.88 billion in 2026, at a compound annual growth rate (CAGR) of 6.0%. The growth observed in the historic period is attributable to the aging female population, increased life expectancy among women, widespread use of hormone replacement therapy, growing awareness of menopausal health, and the expansion of gynecological healthcare services.

The menopausal hot flashes market size is poised for robust expansion in the coming years. It is predicted to escalate to $21.68 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. The projected increase in this period can be attributed to a rising demand for safer non-hormonal treatments, an expansion of healthcare programs focused on menopause, intensified research in women’s health, the growth of online and digital health consultations, and increasing acceptance of alternative therapeutic methods. Significant developments anticipated during the forecast period include a growing preference for non-hormonal treatment alternatives, enhanced awareness and diagnosis of menopausal symptoms, increased adoption of alternative and lifestyle-oriented therapies, the expansion of personalized menopause management strategies, and a higher demand for solutions addressing long-term symptom management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12592&type=smp

What Drivers Are Shaping The Future Growth Of The Menopausal Hot Flashes Market?

The future expansion of the menopausal hot flashes market is anticipated to be propelled by government initiatives aimed at women’s health during menopause. These government efforts for menopausal health encompass dedicated programs, funding, and policy actions intended to enhance care, support research, and improve access to services for women encountering menopause-related symptoms. Such initiatives are on the rise as governments increasingly acknowledge the need for better education, early diagnosis, and effective treatment options to support women’s health throughout the menopausal transition. The menopausal hot flashes market gains from these endeavors by reinforcing research activities, accelerating innovation, and broadening access to evidence-based treatments for symptom relief. For example, in January 2023, the Government of New South Wales, an Australia-based government agency, committed 0.0403 billion over four years (2022–2023 to 2025–2026) to establish up to 16 new programs designed to support women with severe menopausal symptoms. Therefore, government initiatives for women’s health in menopause are significantly contributing to the growth of the menopausal hot flashes market.

What Segment Groups Are Identified Within The Menopausal Hot Flashes Market?

The menopausal hot flashes market covered in this report is segmented –

1) By Type: Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment

2) By Pipeline Analysis: Phase III Drugs, Phase I And II Drugs

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospital Pharmacies

4) By Application: 51-55 Year Old Woman, 46-50 Year Old Woman, 40-45 Year Old Woman

Subsegments:

1) By Hormonal Treatment: Estrogen Therapy, Combined Hormonal Therapy

2) By Non-Hormonal Treatment: Selective Serotonin Reuptake Inhibitors, Gabapentinoids, Clonidine

3) By Alternative Treatment: Herbal Supplements, Acupuncture, Lifestyle Modifications

What Key Trends Are Influencing The Development Of The Menopausal Hot Flashes Market?

Major corporations in the worldwide menopausal hot flashes sector are concentrating on creating advanced treatments, such as non-hormonal neurokinin-3 (NK3) receptor antagonists, to offer safer and more efficient options for women unable or unwilling to use hormone therapy. These non-hormonal NK3 receptor antagonists are targeted medications designed to lessen the occurrence and intensity of vasomotor symptoms, including moderate to severe hot flashes, by inhibiting neurokinin-3 receptors in the brain’s thermoregulatory area. For example, in May 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, secured approval from the Food and Drug Administration (FDA) for Veozah (fezolinetant), an oral drug intended for treating moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Veozah stands as the world’s inaugural non-hormonal NK3 receptor antagonist specifically developed for menopausal hot flashes. It provides a unique non-hormonal mechanism of action, once-daily oral administration, and clinically demonstrated reductions in both the frequency and intensity of vasomotor symptoms, marking a significant step forward for women seeking relief from menopause-related symptoms without hormones.

Which Companies Hold Significant Positions In The Menopausal Hot Flashes Market?

Major companies operating in the menopausal hot flashes market are Pfizer Inc., Johnson & Johnson, The Procter & Gamble Company, Merck & Co. Inc., Bayer AG, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Gedeon Richter Plc, Lupin Limited, Hisamitsu Pharmaceutical Co. Inc., Noven Pharmaceuticals Inc., Ligand Pharmaceuticals Inc., Mithra Pharmaceuticals SA, TherapeuticsMD Inc., Theramex Ltd., Ascend Therapeutics Inc., EndoCeutics Inc., Sermonix Pharmaceuticals LLC, Ralington pharma LLP

Read the full menopausal hot flashes market report here:

https://www.thebusinessresearchcompany.com/report/menopausal-hot-flashes-global-market-report

Which Geographic Regions Are Influencing Demand In The Menopausal Hot Flashes Market?

North America was the largest region in the Menopausal Hot Flashes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menopausal hot flashes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Menopausal Hot Flashes Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12592&type=smp

Browse Through More Reports Similar to the Global Menopausal Hot Flashes Market 2026, By The Business Research Company

Meningococcal Disease Vaccine Global Market Report

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Pneumococcal Vaccine Global Market Report

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Vaccines Global Market Report

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795